Leave your feedback Share Copy URL https://gographicsoutput.com/video/RCdYCZaRbnM.html Email Facebook Twitter LinkedIn Pinterest Tumblr Share on Facebook Share on Twitter WASHINGTON President Donald Trump’s acting attorney general on Thursday signed an order reclassifyin [5RZP1xVtysv] Health Updated on August 06, 2026 EDT — Published on August 06, 2026 EDT WASHINGTON President Donald Trump’s acting attorney general on Thursday signed an order reclassifying state-licensed medical marijuana as a less-dangerous drug, a major policy shift long sought by advocates who said cannabis should never have been treated like heroin by the federal government. The order signed by Acting Attorney General Todd Blanche does not legalize marijuana for medical or recreational use under U.S. law. But it changes the way it’s regulated. The measure reflects a move to treat state-licensed medical cannabis more like other regulated medicines, rather than a controlled substance on par with heroin. Supporters say the change could ease regulatory burdens and support research, while opponents argue it risks expanding access and blurring lines between medical use and illegal distribution. The development represents a landmark shift in federal drug policy, even as many questions remain about implementation and impact on patients and states. Officials caution effects depend on regulation. Like 👍 Subscribe 🔔 and stay informed. Visit NHENews.COM for more top headlines. J9ltEoxsCqd fCNXhRoYY4Y GWwUKbjCO1Y e8RSzTktKp3
WASHINGTON President Donald Trump’s acting attorney general on Thursday signed an order reclassifying state-licensed medical marijuana as a less-dangerous drug, a major policy shift long sought by advocates who said cannabis should never have been treated like heroin by the federal government. The order signed by Acting Attorney General Todd Blanche does not legalize marijuana for medical or recreational use under U.S. law. But it changes the way it’s regulated. The measure reflects a move to treat state-licensed medical cannabis more like other regulated medicines, rather than a controlled substance on par with heroin. Supporters say the change could ease regulatory burdens and support research, while opponents argue it risks expanding access and blurring lines between medical use and illegal distribution. The development represents a landmark shift in federal drug policy, even as many questions remain about implementation and impact on patients and states. Officials caution effects depend on regulation. Like 👍 Subscribe 🔔 and stay informed. Visit NHENews.COM for more top headlines. J9ltEoxsCqd fCNXhRoYY4Y GWwUKbjCO1Y e8RSzTktKp3